We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher. In this article, we are ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Jumpcode Genomics ('Jumpcode'), a life science tools company ...

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with ...

Merck (MRK) announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the subcutaneous administration of ...

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...

Despite this potential, the stock has fallen by 25% in the past 12 months -- so is it a bargain buy right now? During the ...

Merck & Co. is flexing its dividend muscles with 14 years of consecutive growth and a yield that's juicier than a ripe ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the ...

Merck last year signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug to ...